Specialty Pharmacy Spend Now Exceeds 55% of Total Drug Costs for Most Employers: What to Do About It

Why a 91% Generic Rate Isn't Moving Your Pharmacy Needle Anymore

I sat down last week with the HR director of a 900-employee manufacturer who was stunned by her latest pharmacy claims report. Her team's generic dispensing rate had hit 91.7% for Q1, well above the national benchmark. But the CFO was staring at a $1.31 million annual pharmacy spend, and the trend line was heading north, not south. The root cause was hiding in plain sight: specialty drugs accounted for 56% of their prescription costs, despite only 1.4% of members using a specialty medication.

This scenario repeats itself everywhere, from 250-life law firms to 10,000-employee school systems. You can run generics as high as you want, but when a handful of claims for Humira, Dupixent, and Stelara average $6,000 per script, the math gets ugly fast. Most employers I advise now see specialty at 52-58% of drug spend, up from 38-42% just five years ago. Chasing incremental generic improvements won’t solve the new math. It’s time to shift the focus.

If you want a current pulse on specialty utilization or reference clinical coverage for a complex drug, bookmark ClinicalRx.ai. Real-world data beats canned PBM presentations every time.

Where Specialty Spend Hides, and How to Find It

A surprising number of plan sponsors can’t say with confidence how much of their spend is specialty, or what’s driving it. PBM reports can bury the lead, lumping specialty into mail order or separating drugs by therapy area rather than spend category. Start by demanding quarterly reports that break out specialty vs. non-specialty by total spend, script count, and unique users. If your PBM won’t deliver that, ask your consultant or use an independent claims analyzer like RxPBM.ai.

Don’t stop at the percentage of spend. Dig into the top 25 drugs by cost, identifying which are self-injectables (like Cimzia or Skyrizi, often used at home) versus infused drugs (like Remicade, billed through the medical benefit). For one 1,200-life tech group I worked with, half their specialty outlay for 2023 came from three anti-inflammatory drugs, Humira, Stelara, and Enbrel. Just seventeen people out of 1,200 accounted for $670,000 of pharmacy claims. Once we mapped this to eligibility, we could start weighing targeted interventions.

If you’re seeing specialty as a line item of more than 54-55% of your annual pharmacy spend, you’re not an outlier anymore. That’s the new baseline for employer plans covering under 10,000 lives, especially if you have a younger, commercially insured group.

Concrete Moves: Biosimilars, Copay Assistance, and Clinical Edits

Many HR teams ask, “How much can we really save without upending employee satisfaction?” The honest answer, some interventions can deliver real value, others less so. Here’s what’s making a difference for mid-size and large employers right now.

Biosimilar adoption: The Humira biosimilar wave was long overdue. As of mid-2024, at least eight biosimilars (Hadlima, Hyrimoz, Cyltezo, Yuflyma, others) are on the market, with discounts of 40-60% off Humira’s $6,900 monthly list price. For a 2,000-employee utility company, moving 40 Humira patients to biosimilars saved roughly $680,000 annually once the plan and PBM enforced a step therapy edit. Not all employees loved the switch, but careful communication and clinical support smoothed most of the bumps. If your PBM or stop-loss carrier blocks biosimilars in favor of legacy rebates, you’re likely leaving six figures per year on the table.

Maximizing manufacturer copay assistance: Most specialty drugs come with robust manufacturer copay cards or patient assistance programs. Plans structured as non-ACA-compliant (grandfathered or self-insured) can often use advanced copay accumulator and maximizer programs to offset spend. For commercial plans, this might mean $40,000-$120,000 in annual savings for a 500-life group, depending on the mix of drugs. It’s critical to confirm your PBM is capturing these dollars, not just letting manufacturer money reduce the member’s cost while still charging the plan the full contracted rate. This is an area where PBM contract language and operational execution matter deeply.

Utilization management for high-dollar therapies: Don’t just accept “standard PBM prior auth” as your only gatekeeper. Ask questions: Are your PA criteria stricter for newer gene therapies, or is every request rubber-stamped? For the new GLP-1s (semaglutide, tirzepatide), do you require documented weight loss attempts, metabolic syndrome evidence, or is a diagnosis code and BMI enough? One employer I worked with kept their annual GLP-1 pharmacy spend under $90,000 by approving use only for diabetes, not general weight loss. Another with looser controls topped $300,000 for the same headcount in just nine months.

You don’t have to implement every program at once. Start with a pilot or focus on a drug class that’s spiking in your group. A practical step is engaging a pharmacy benefits consultant to audit your specialty drug mix and suggest targeted edits, rather than lurching into a full PBM carve-out.

Communicating Specialty Changes Without Employee Revolt

The reality: specialty management creates friction. No one celebrates when they’re told their familiar auto-injector is changing or their copay card now needs a new process. But candid, proactive communication can avoid the worst fallout.

Here’s what works. Get out ahead of changes with brief, plain-English FAQs sent directly to impacted members, not buried in a 22-page open enrollment guide. When a 480-life engineering firm introduced a biosimilar transition for Enbrel, we scheduled a live Q&A webinar for affected employees and brought in a clinical pharmacist for reassurance. Less than 10% of members raised concerns, and only two appealed the switch.

Don’t be afraid to explain the financials. Employees are more receptive to a $1,200 annual plan savings per member when they know it helps keep premiums steady and protects broader benefits. If you get pushback, offer to connect specific members with a pharmacist or nurse case manager. And always make sure HR staff can answer at least the basic “why” and “how” questions about the change.

If you want real-world testimonials or data on the patient experience with biosimilars and specialty transitions, check out RxNews.ai. Keeping a pulse on industry trends helps you prepare for tough conversations.

Final Thoughts: Specialty Is the New Pharmacy Battleground

Specialty pharmacy is no longer a niche concern. It’s the main driver of pharmacy inflation in almost every employer plan I touch, big or small. You can’t ignore it or expect traditional levers, like increasing generic rates or nudging more mail order, to get spend under control.

Start by getting granular data, then target the biggest drivers with smart, measured interventions. Biosimilars, copay maximizers, and tighter clinical edits aren’t silver bullets, but for most groups, they’re the difference between a runaway trend and a manageable one.

Don’t go it alone. Bring in a pharmacy benefits consultant or data partner who has done this before. And above all, communicate changes clearly, with numbers your employees can relate to. That’s how you pull specialty pharmacy spend out of the red zone, and keep it there.